To evaluate the prognostic significance of the 18F-FDG uptake ratio between the brain/cerebellum and liver in patients with multiple myeloma undergoing CAR T cell therapy, specifically focusing on survival outcomes.
Key Findings:
Patients with a brain/liver ratio 2.5.
CLIP has shown a negative impact on progression-free survival (PFS) with hazard ratios between 3.1 and 3.7 in various lymphoid malignancies.
Optimal thresholds for cerebrum/cerebellum to liver ratios range between 2 and 4 across studies, indicating variability in prognostic significance.
Interpretation:
The study suggests that the 18F-FDG uptake ratios can serve as valuable prognostic indicators, with the cerebellum/liver ratio potentially offering more consistent results than brain/liver ratios, which may enhance clinical decision-making.
Limitations:
Confounding factors such as age and glycemia may influence uptake measurements, potentially skewing results.
Dichotomization of continuous variables may lead to loss of information and misclassification, impacting the reliability of findings.
Conclusion:
Further research is needed to clarify the role of these uptake ratios in conjunction with existing prognostic indexes, particularly focusing on the impact of confounding factors and the development of more nuanced measurement approaches.
